Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Vitacost Weighs Options After Losses; Shareholder Airs Complaints

This article was originally published in The Tan Sheet

Executive Summary

Activist shareholder Consac urges Vitacost.com to sell after operating losses four years in a row, despite close to $400 million in annual sales.

You may also be interested in...



Kroger Dives Into Online Supplement Sales, Vitacost Stays Afloat With Merger

Kroger will pay approximately $280 million for Vitacost.com, valuing the online supplement and health food retailer at $8 per share, a premium of 51% on it closing share price on Feb. 19, 2014, the day before a major shareholder asked the firm’s management to consider selling.

Kroger Dives Into Online Supplement Sales, Vitacost Stays Afloat With Merger

Kroger will pay approximately $280 million for Vitacost.com, valuing the online supplement and health food retailer at $8 per share, a premium of 51% on it closing share price on Feb. 19, 2014, the day before a major shareholder asked the firm’s management to consider selling.

In Brief: Vitacost Bends To Investors, Actavis Makes Asian Moves, DSM Courts Vitamin C Firm

Truce for Vitacost, investors; Actavis buys Silom Medical; DSM courts Aland; ChromaDex shares product libraries; Tenn. blocks drug felons buying PSE; FTC finalizes L’Occitane settlement; and more In Brief.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS106790

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel